Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Moderna, Inc.

Market Cap 25.38B 22.14B 20.49B 19.22B 35.97B 2,393B 36.24B 243B 94.08B 1,178B 95.26B 93.21B 4,096B P/E 2026 *
-7.4x
P/E 2027 * -13.5x
Enterprise Value 21.82B 19.03B 17.62B 16.52B 30.92B 2,058B 31.15B 209B 80.88B 1,013B 81.9B 80.14B 3,522B EV / Sales 2026 *
10.5x
EV / Sales 2027 * 9.2x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -
1 day+3.50%
1 week+28.15%
Current month+35.54%
1 month+32.92%
3 months+24.48%
6 months+89.23%
Current year+116.89%
1 week 49.84
Extreme 49.8401
67.74
1 month 43.9
Extreme 43.9
67.74
Current year 29.81
Extreme 29.81
67.74
1 year 22.28
Extreme 22.28
67.74
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 2011-02-28
Director of Finance/CFO 49 2022-09-05
President 50 2024-10-31
Director TitleAgeSince
Chairman 62 2012-01-31
Director/Board Member 54 2011-02-28
Director/Board Member 69 2019-12-10
Date Insider Type Main position Quantity % Market Cap.
06-14Fiscal year

Chairperson

160,008 0.0403%
06-04Fiscal year

Chief Financial Officer

29,301 0.0074%
06-04Fiscal year

General Counsel

29,301 0.0074%
Change 5-day change 1-year change 3-year change Capi.($)
+3.50%+28.15%+146.95%-48.51% 25.38B
+0.33%-0.36%+19.66%-21.92% 62.05B
+0.20%-9.17%+58.54%+194.67% 54.52B
-3.92%+37.40%+37.40%+37.40% 41.55B
+7.62%+8.19%-51.58%-58.97% 39.06B
-1.05%-1.73%+54.74%-33.09% 29.02B
-0.78%-9.50%+43.47%+59.06% 19.62B
+1.74%-0.39%-1.99%+126.64% 16.89B
-0.05%+0.23%+61.48%+104.74% 15.89B
-1.66%-0.79%+58.81%+301.15% 12.98B
Average +0.59%+2.31%+42.75%+66.12% 31.7B
Weighted average by Cap. +0.68%+1.58%+37.32%+47.90%

Financials

2026 *2027 *
Net sales 2.09B 1.82B 1.69B 1.58B 2.96B 197B 2.98B 19.98B 7.74B 96.88B 7.83B 7.67B 337B 2.51B 2.19B 2.03B 1.9B 3.56B 237B 3.59B 24.05B 9.31B 117B 9.43B 9.23B 405B
Net income -3.4B -2.97B -2.75B -2.58B -4.82B -321B -4.86B -32.59B -12.62B -158B -12.78B -12.5B -549B -1.84B -1.61B -1.49B -1.39B -2.61B -174B -2.63B -17.62B -6.82B -85.41B -6.91B -6.76B -297B
Net Debt -3.56B -3.11B -2.87B -2.7B -5.04B -336B -5.08B -34.08B -13.19B -165B -13.36B -13.07B -574B -2.27B -1.98B -1.84B -1.72B -3.22B -214B -3.25B -21.76B -8.43B -106B -8.53B -8.35B -367B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
26-06-18 63.96 $ +3.50% 24,078,835
26-06-17 61.80 $ +11.55% 12,447,970
26-06-16 55.40 $ +6.27% 13,050,523
26-06-15 52.13 $ +4.45% 6,342,068
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
63.96USD
Average target price
43.30USD
Spread / Average Target
-32.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!